KLRS

Kalaris Therapeutics, Inc. Common Stock

$4.90 -7.02%

Recent alerts on KLRS

All signals →

Insider trade Purchase by Samsara BioCapital, L.P.

Insider trade Purchase by Samsara BioCapital GP, LLC

Insider trade Purchase by Samsara Opportunity Fund, L.P.

Insider trade Purchase by Samsara Opportunity Fund GP, LLC

Insider trade Purchase by AKKARAJU SRINIVAS

SEC filing KLRS Reports $104.9M Cash Balance, $7.6M R&D Expenses, $10.9M Net Loss, Advances Phase 1b/2 Trial

SEC filing KLRS Announces CFO Matthew Gall Resignation Effective April 14 2026 Brett Hagen Becomes Principal Financial Officer

Insider trade Sale by Brett R Hagen (Chief Accounting Officer)

SEC filing KLRS Reports $118M Cash, $30.8M R&D Spend, Positive Phase 1a nAMD Data, $50M Placement

SEC filing KLRS Announces $50M Oversubscribed Private Placement, TH103 Phase 1b/2 Data 1H 2027, Cash Runway to Q4 2027

Insider trade Purchase by Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC

Scanner Unusual volume (z=7.5)

Get push alerts for KLRS

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS